Developments in AI are leading to bioinformatics strengthening important advances in drug development and re-purposing. Although mathematical methods and computer programs, as such, are not patentable at the European Patent Office, the vast amount of genetic information which can now be gleaned by powerful nucleic acid sequencing techniques and developments in AI, means bioinformatics underpins many commercially important inventions for which protection can be obtained.
These inventions span the fields of personalised medicine, non-invasive foetal testing, innovations made possible by the latest sequencing techniques for interrogation of the human genome, and developments arising from growing knowledge of the genetic diversity of microbes.
HGF works with clients in fields ranging from major global corporations to start-up businesses, advising on, and patenting bioinformatics’ applications. The specialist attorneys keep pace with fast-moving developments in complex, multi-disciplinary fields, and expertly navigate and challenge patenting requirements as they impact on the areas of computer-implemented inventions and discoveries of the natural world.
Our dedicated team of individuals, with experience of commercial application of bioinformatics across life sciences, pharmaceuticals and electronics teams, provide cross-disciplinary IP strategies. This multidisciplinary approach combines members of the specialist microbiome team, attorneys with deep experience in computer software inventions, and HGF’s legal specialists with expertise in database rights and data protection.
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
How to streamline the trade mark selection process by conducting effective, in-house ‘dirty searches’. Selecting the right trade mark for your new healthcare product is a critically important task. Consumers …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
World Intellectual Property Day is on 26th April. This year’s theme is IP & SME’s: Taking your ideas to market. World IP day 2021 shines a light on the critical role of …Event details
‘IP & data protection for alternative proteins: how to protect your products in the EU’ webinar will be held on Tuesday 18th May. Join this webinar by BGP, HGF & …Event details